.Pharmacolibrary.Drugs.ATC.N.N02CD04

Information

Ubrogepant is an orally administered, small molecule, calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. It is currently approved and used clinically.

Pharmacokinetics

Pharmacokinetic parameters obtained from healthy adult subjects, predominantly female, after single oral doses in the therapeutic range.

References

1. Jakate, A, et al., & Lipton, RB (2021). Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study. Headache 61(4) 642–652. DOI:10.1111/head.14095 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33818780

2. Li, CC, et al., & Kothare, PA (2018). Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling. Journal of clinical pharmacology 58(3) 294–303. DOI:10.1002/jcph.1021 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29136283

3. Li, CC, et al., & Kothare, PA (2020). Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment. Clinical and translational science 13(3) 482–490. DOI:10.1111/cts.12730 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31758661

Revisions

• 06/2025 initial generated model